Beximco Pharma plans subsidiary to diversify product portfolio

ملخص مفصل

Beximco Pharmaceuticals PLC, one of the leading drug makers in Bangladesh, plans to establish a wholly owned subsidiary to manufacture and market herbal medicinal products as part…

Beximco Pharmaceuticals PLC, one of the leading drug makers in Bangladesh, plans to establish a wholly owned subsidiary to manufacture and market herbal medicinal products as part of its efforts to diversify its product portfolio and expand its presence in the healthcare market.

The board of Beximco Pharma decided to incorporate the new entity, Beximco Pharma Nutraceuticals Ltd, at a meeting held on November 12, 2026, the listed company said in a disclosure to the Dhaka Stock Exchange (DSE) today.

The proposed company will have an authorised share capital of Tk 100 crore, divided into 10 crore ordinary shares of Tk 10 each, and an initial paid-up capital of Tk 10 crore, Beximco Pharma said.

Shares of the drug maker rose 3.97 percent to Tk 149.20 as of 1:47pm today.

The incorporation of the subsidiary and commencement of its operations will be subject to obtaining the necessary statutory and regulatory approvals, Beximco Pharma said, adding that it does not anticipate any material impact on its financial performance in the immediate or medium term from the initiative.

The drug maker posted an 8 percent increase in earnings per share (EPS) to Tk 5.72 for the July-September quarter of 2026, from Tk 5.30 in the same period a year earlier.

The company also reported higher cash flow, which measures the cash generated from core business operations, during the period.

Beximco Pharma’s net operating cash flow per share (NOCFPS) grew 31 percent year-on-year to Tk 8.06 in the July-September quarter of 2026, from Tk 6.14 in the same period a year earlier, the company said.

مطلع المقال، مقتطف من The Daily Star. لقراءة المقال كاملًا، افتحه على موقع الناشر.